

**PROQR THERAPEUTICS N,V,
Unaudited Condensed Consolidated Statement of Financial Position**

	March 31, 2019	December 31, 2018
	<i>€ 1,000</i>	<i>€ 1,000</i>
Assets		
Current assets		
Cash and cash equivalents	94,080	105,580
Prepayments and other receivables	2,088	1,544
Social security and other taxes	1,530	1,243
Total current assets	97,698	108,367
Property, plant and equipment	3,925	1,864
Intangible assets	—	—
Total assets	101,623	110,231
Equity and liabilities		
Equity		
Equity attributable to owners of the Company	81,129	92,915
Non-controlling interests	(317)	(230)
Total equity	80,812	92,685
Current liabilities		
Borrowings	95	—
Lease liabilities	1,167	—
Trade payables	64	135
Social security and other taxes	14	—
Pension premiums	3	7
Deferred income	—	545
Other current liabilities	8,352	7,473
Total current liabilities	9,695	8,160
Borrowings	10,208	9,386
Lease liabilities	908	—
Total liabilities	20,811	17,546
Total equity and liabilities	101,623	110,231

PROQR THERAPEUTICS N.V.**Unaudited Condensed Consolidated Statement of Profit or Loss and OCI**

(€ in thousands, except share and per share data)

	Three-month period ended March 31	
	2019	2018
	€ 1,000	€ 1,000
Other income	416	499
Research and development costs	(11,963)	(7,685)
General and administrative costs	(3,191)	(2,672)
Total operating costs	(15,154)	(10,357)
Operating result	(14,738)	(9,858)
Finance income and expense	494	(859)
Result before corporate income taxes	(14,244)	(10,717)
Income taxes	—	—
Result for the period	(14,244)	(10,717)
Other comprehensive income	12	(26)
Total comprehensive income	(14,232)	(10,743)
Result attributable to		
Owners of the Company	(14,157)	(10,659)
Non-controlling interests	(87)	(58)
	(14,244)	(10,717)
Share information		
Weighted average number of shares outstanding ¹	38,885,428	31,921,865
Earnings per share attributable to the equity holders of the Company (expressed in Euro per share)		
Basic loss per share ¹	(0.36)	(0.33)
Diluted loss per share ¹	(0.36)	(0.33)

1. For this period presented in these financial statements, the potential exercise of share options is not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in this period.

ordinary shares									
Issue of treasury shares	—	—	—	—	—	—	—	—	—
Share options lapsed	—	—	—	—	—	—	—	—	—
Share options exercised	—	—	71	(49)	—	49	71	—	—
Balance at March 31, 2019	43,149,987	1,726	235,815	13,019	120	(169,551)	81,129		(317)

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Cash Flows

	Three-month period ended March 31,	
	2019	2018
	€ 1,000	€ 1,000
Cash flows from operating activities		
Net result	(14,244)	(10,717)
Adjustments for:		
— Depreciation	521	240
— Share-based compensation	2,288	871
— Financial income and expenses	(494)	859
— Net foreign exchange gain / (loss)	12	(26)
Changes in working capital	(474)	(936)
<i>Cash used in operations</i>	<i>(12,391)</i>	<i>(9,709)</i>
Corporate income tax paid	—	—
Interest received	54	—
Interest paid	(27)	(1)
<i>Net cash used in operating activities</i>	<i>(12,364)</i>	<i>(9,710)</i>
Cash flow from investing activities		
Purchases of intangible assets	—	—
Purchases of property, plant and equipment	(223)	(4)
<i>Net cash used in investing activities</i>	<i>(223)</i>	<i>(4)</i>
Cash flow from financing activities		
Proceeds from issuance of shares, net of transaction costs	—	—
Proceeds from exercise of share options	71	—
Proceeds from borrowings	—	101
Proceeds from convertible loans	690	200
Redemption of financial lease	(284)	—
<i>Net cash generated by financing activities</i>	<i>477</i>	<i>301</i>
Net increase/(decrease) in cash and cash equivalents	(12,110)	(9,413)

Currency effect cash and cash equivalents	610	(685)
Cash and cash equivalents, at beginning of the period	105,580	48,099
Cash and cash equivalents at the end of the period	94,080	38,001